Clinical Trial

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Name: Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors. — clinical trial record (NCT07040943)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 1

View on ClinicalTrials.gov →

Summary

This study aims to investigate the safety and efficacy of the IL-22BP in patients with refractory malignant solid tumors.

Protocol Amendment History 2 changes

critical Trial completed 2026-07-31

notable Primary completion moved earlier: 2026-07-01 -> 2026-01-20 2026-07-31

Trial Details

NCT Number	NCT07040943
Lead Sponsor	West China Hospital
Conditions	Refractory Malignant Solid Tumors, mRNA Vaccine, Interleukin
Enrollment	6 participants
Start Date	2025-06-29
Primary Completion	2026-01-20 (estimated)
Study Completion	2026-07-20 (estimated)
Updated on ClinicalTrials.gov	2026-07-30